Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: A preliminary study using in vivo proton magnetic resonance spectroscopy (1H MRS)

Journal of Neurodevelopmental Disorders

Volumn 6, Issue 1, 2014, Pages

  Tan, Giles M Y ^a,b   Beacher, Felix ^a   Daly, Eileen ^a   Horder, Jamie ^a   Prasher, Verinder ^c   Hanney, Maria Luisa ^d   Morris, Robin ^a   Lovestone, Simon ^a   Murphy, Kieran C ^e   Simmons, Andrew ^a,f   Murphy, Declan G M ^a,f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c Greenfields Monyhull Hospital   (United Kingdom)

^d Northgate Hospital   (United Kingdom)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^f SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

1H MRS; Alzheimer's disease; Dementia; Down syndrome; Glutamate glutamine (Glx); Hippocampus; Intellectual disability; Magnetic resonance spectroscopy

Indexed keywords

GLUTAMIC ACID; GLUTAMINE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; DOWN SYNDROME; FEMALE; GLUTAMATERGIC SYNAPSE; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84960082575     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/1866-1955-6-42     Document Type: Article

References (74)

1. Wisniewski KE: Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl 1990, 7:274-281.
2. Schupf N, Sergievsky GH: Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 2002, 180:405-410. 10.1192/bjp.180.5.405
3. Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, van Wijk J: Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard 1997, 101:400-412.
4. Margallo-Lana ML, Moore PB, Kay DW, Perry RH, Reid BE, Berney TP, Tyrer SP: Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J Intellect Disabil Res 2007, 51:463-477. 10.1111/j.1365-2788.2006.00902.x
5. Sheehan R, Ali A, Hassiotis A: Dementia in intellectual disability. Curr Opin Psychiatry 2014, 27:143-148. 10.1097/YCO.0000000000000032
6. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC: Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43:380-383. 10.1002/ana.410430316
7. Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N: Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007, 120:e1465-e1471. 10.1542/peds.2006-3448
8. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G, Fernandez M, Giuliani A, Calza L, Bartesaghi R: Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010, 30:8769-8779. 10.1523/JNEUROSCI.0534-10.2010
9. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, Mobley WC: Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 2004, 480:281-298. 10.1002/cne.20337
10. Beacher F, Simmons A, Daly E, Prasher V, Adams C, Margallo-Lana ML, Morris R, Lovestone S, Murphy K, Murphy DG: Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2005, 62:1360-1365. 10.1001/archpsyc.62.12.1360
11. Lamar M, Foy CM, Beacher F, Daly E, Poppe M, Archer N, Prasher V, Murphy KC, Morris RG, Simmons A, Lovestone S, Murphy DG: Down syndrome with and without dementia: an in vivo proton magnetic resonance spectroscopy study with implications for Alzheimer's disease. Neuroimage 2011, 57:63-68. 10.1016/j.neuroimage.2011.03.073
12. Robbins TW, Murphy ER: Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 2006, 27:141-148. 10.1016/j.tips.2006.01.009
13. Cull-Candy S, Brickley S, Farrant M: NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001, 11:327-335. 10.1016/S0959-4388(00)00215-4
14. McKernan MG, Shinnick-Gallagher P: Fear conditioning induces a lasting potentiation of synaptic currents in vitro. Nature 1997, 390:607-611. 10.1038/37605
15. Rogan MT, Staubli UV, LeDoux JE: AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J Neurosci 1997, 17:5928-5935.
16. Doraiswamy PM: Alzheimer's disease and the glutamate NMDA receptor. Psychopharmacol Bull 2003, 37:41-49.
17. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA: NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996, 17:348-355. 10.1016/S0165-6147(96)10046-8
18. Francis PT, Sims NR, Procter AW, Bowen DM: Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 1993, 60:1589-1604. 10.1111/j.1471-4159.1993.tb13381.x
19. Francis PT: The interplay of neurotransmitters in Alzheimer's disease. CNS Spectrosc 2005, 10:6-9.
20. Marlatt MW, Webber KM, Moreira PI, Lee HG, Casadesus G, Honda K, Zhu X, Perry G, Smith MA: Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 2005, 12:1137-1147. 10.2174/0929867053764644
21. Lipton SA: Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004, 1:101-110. 10.1602/neurorx.1.1.101
22. Glodzik L, King KG, Gonen O, Liu S, De Santi S, de Leon MJ: Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1005-1012. 10.1016/j.pnpbp.2008.01.016
23. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324. 10.1001/jama.291.3.317
24. Kurt MA, Davies DC, Kidd M, Dierssen M, Florez J: Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res 2000, 858:191-197. 10.1016/S0006-8993(00)01984-3
25. Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, Del Rio J: Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007, 25:281-290. 10.1111/j.1460-9568.2006.05259.x
26. Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, Klann E, Galdzicki Z: Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J Neurochem 2006, 98:1266-1277. 10.1111/j.1471-4159.2006.03971.x
27. Begni B, Brighina L, Fumagalli L, Andreoni S, Castelli E, Francesconi C, Del Bo R, Bresolin N, Ferrarese C: Altered glutamate uptake in peripheral tissues from Down syndrome patients. Neurosci Lett 2003, 343:73-76. 10.1016/S0304-3940(03)00260-X
28. Reynolds GP, Warner CE: Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. Neurosci Lett 1988, 94:224-227. 10.1016/0304-3940(88)90299-6
29. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G: Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn Schmiedebergs Arch Pharmacol 2001, 363:139-145. 10.1007/s002100000346
30. Risser D, Lubec G, Cairns N, Herrera-Marschitz M: Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 1997, 60:1231-1237. 10.1016/S0024-3205(97)00067-2
31. Miller BL: A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991, 4:47-52. 10.1002/nbm.1940040203
32. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB: Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996, 7:1397-1400. 10.1097/00001756-199605310-00014
33. Novotny EJ Jr, Fulbright RK, Pearl PL, Gibson KM, Rothman DL: Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol 2003,54(Suppl 6):S25-S31.
34. Bak LK, Schousboe A, Waagepetersen HS: The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006, 98:641-653. 10.1111/j.1471-4159.2006.03913.x
35. Smigielska-Kuzia J, Sobaniec W: Brain metabolic profile obtained by proton magnetic resonance spectroscopy HMRS in children with Down syndrome. Adv Med Sci 2007,52(Suppl 1):183-187.
36. Smigielska-Kuzia J, Bockowski L, Sobaniec W, Kulak W, Sendrowski K: Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome. Pharmacol Rep 2010, 62:1070-1077. 10.1016/S1734-1140(10)70369-8
37. Aylward EH, Li Q, Honeycutt NA, Warren AC, Pulsifer MB, Barta PE, Chan MD, Smith PD, Jerram M, Pearlson GD: MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Am J Psychiatry 1999, 156:564-568.
38. Beacher F, Daly E, Simmons A, Prasher V, Morris R, Robinson C, Lovestone S, Murphy K, Murphy DG: Alzheimer's disease and Down's syndrome: an in vivo MRI study. Psychol Med 2009, 39:675-684. 10.1017/S0033291708004054
39. Tan GMY, Murphy DGM: Brain MRI findings in down syndrome and dementia. Med Men Geist Mehrf Beh 2011, 8:30-38.
40. Ball MJ, Nuttall K: Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in down syndrome: quantitative comparison with Alzheimer dementia. Ann Neurol 1980, 7:462-465. 10.1002/ana.410070512
41. Braak H, Braak E: Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging 1994, 15:355-356. discussion 379-380 10.1016/0197-4580(94)90032-9
42. WHO: The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
43. Simmons A, Arridge SR, Barker GJ, Williams SC: Simulation of MRI cluster plots and application to neurological segmentation. Magn Reson Imaging 1996, 14:73-92. 10.1016/0730-725X(95)02040-Z
44. Robertson DM, van Amelsvoort T, Daly E, Simmons A, Whitehead M, Morris RG, Murphy KC, Murphy DG: Effects of estrogen replacement therapy on human brain aging: an in vivo 1H MRS study. Neurology 2001, 57:2114-2117. 10.1212/WNL.57.11.2114
45. Cutter WJ, Daly EM, Robertson DM, Chitnis XA, van Amelsvoort TA, Simmons A, Ng VW, Williams BS, Shaw P, Conway GS, Skuse DH, Collier DA, Craig M, Murphy DG: Influence of X chromosome and hormones on human brain development: a magnetic resonance imaging and proton magnetic resonance spectroscopy study of Turner syndrome. Biol Psychiatry 2006, 59:273-283. 10.1016/j.biopsych.2005.06.026
46. Simmons A, Smail M, Moore E, Williams SC: Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magn Reson Imaging 1998, 16:319-330. 10.1016/S0730-725X(97)00280-4
47. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C: MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 2009, 1180:47-55. 10.1111/j.1749-6632.2009.05063.x
48. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C: The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011, 26:75-82. 10.1002/gps.2491
49. Christiansen P, Toft P, Larsson HB, Stubgaard M, Henriksen O: The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging 1993, 11:799-806. 10.1016/0730-725X(93)90197-L
50. Provencher SW: Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679. 10.1002/mrm.1910300604
51. Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L: CAMCOG-a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. Br J Clin Psychol 1995,34(Pt 4):529-541.
52. Roth M, Huppert FA, Mountjoy CQ, Tym E: The Revised Cambridge Examination for Mental Disorders of the Elderly. Cambridge: Cambridge University Press; 1998.
53. Hon J, Huppert FA, Holland AJ, Watson P: Neuropsychological assessment of older adults with Down's syndrome: an epidemiological study using the Cambridge Cognitive Examination (CAMCOG). Br J Clin Psychol 1999,38(Pt 2):155-165.
54. Muir JL: Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav 1997, 56:687-696. 10.1016/S0091-3057(96)00431-5
55. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS: Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994, 116:143-151. 10.1007/BF02245056
56. Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, Basile J, Gasser R, Moreau JL, Wettstein JG, Buettelmann B, Knust H, Thomas AW, Trube G, Hernandez MC: RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 2009, 202:207-223. 10.1007/s00213-008-1357-7
57. Buhot MC, Martin S, Segu L: Role of serotonin in memory impairment. Ann Med 2000, 32:210-221. 10.3109/07853890008998828
58. Drachman DA: Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977, 27:783-790. 10.1212/WNL.27.8.783
59. Ernst T, Chang L, Melchor R, Mehringer CM: Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997, 203:829-836. 10.1148/radiology.203.3.9169712
60. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R: Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2011, 32:802-810. 10.1016/j.neurobiolaging.2009.05.002
61. Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, Costa AC: Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2012, 2:e141. 10.1038/tp.2012.66
62. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C: Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 379:528-536. 10.1016/S0140-6736(11)61676-0
63. Tan GMY, Murphy DGM: Down syndrome: genetic and clinical overlap with dementia. In Principles and Practice of Geriatric Psychiatry. 3rd edition. Edited by: Abou-Saleh MM, Katona CLE, Kumar A. New York: Wiley; 2011:281-286.
64. Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, Small GW: Positron emission tomography of brain {beta}-amyloid and tau levels in adults with Down syndrome. Arch Neurol 2011, 68:768-774.
65. Coppus AM, Evenhuis HM, Verberne GJ, Visser FE, Arias-Vasquez A, Sayed-Tabatabaei FA, Vergeer-Drop J, Eikelenboom P, van Gool WA, van Duijn CM, Coppus AMW: The impact of apolipoprotein E on dementia in persons with Down's syndrome. Neurobiol Aging 2008, 29:828-835. 10.1016/j.neurobiolaging.2006.12.013
66. Jones EL, Margallo-Lana M, Prasher VP, Ballard CG: The extended tau haplotype and the age of onset of dementia in Down syndrome. Dement Geriatr Cogn Disord 2008, 26:199-202. 10.1159/000152044
67. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, Tabara Y, Miki T, Akatsu H, Kosaka K, Funakoshi E, Nishitomi K, Sakaguchi G, Kato A, Hattori H, Uema T, Takeda M: The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007, 16:15-23.
68. Margallo-Lana M, Morris CM, Gibson AM, Tan AL, Kay DW, Tyrer SP, Moore BP, Ballard CG, Kay DWK: Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology 2004, 62:1996-1998. 10.1212/01.WNL.0000129275.13169.BE
69. Schupf N, Winsten S, Patel B, Pang D, Ferin M, Zigman WB, Silverman W, Mayeux R: Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome. Neurosci Lett 2006, 406:298-302. 10.1016/j.neulet.2006.07.062
70. Bush A, Beail N: Risk factors for dementia in people with Down syndrome: issues in assessment and diagnosis. Am J Ment Retard 2004, 109:83-97. 10.1352/0895-8017(2004)109<83:RFFDIP>2.0.CO;2
71. Carta MG, Serra P, Ghiani A, Manca E, Hardoy MC, Del Giacco GS, Diaz G, Carpiniello B, Manconi PE: Chemokines and pro-inflammatory cytokines in Down's syndrome: an early marker for Alzheimer-type dementia? Psychother Psychosom 2002, 71:233-236. 10.1159/000063649
72. Whitaker-Azmitia PM: Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001, 56:479-485. 10.1016/S0361-9230(01)00615-3
73. Schott JM, Frost C, MacManus DG, Ibrahim F, Waldman AD, Fox NC: Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain 2010, 133:3315-3322. 10.1093/brain/awq208
74. Berry GT, Mallee JJ, Kwon HM, Rim JS, Mulla WR, Muenke M, Spinner NB: The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 1995, 25:507-513. 10.1016/0888-7543(95)80052-N